CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges

Yongxian Hu; Elaine Tan Su Yin; Yingying Yang; Hengwei Wu; Guoqing Wei; Junwei Su; Qu Cui; Aiyun Jin; Li Yang; Shan Fu; Jianfeng Zhou; Lugui Qiu; Xi Zhang; Aibin Liang; Hongmei Jing; Yuhua Li; Didier Blaise; Mohamad Mohty; Arnon Nagler; He Huang

doi:10.1016/j.retram.2020.06.003

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges

Yongxian Hu, Elaine Tan Su Yin, Yingying Yang, Hengwei Wu, Guoqing Wei, Junwei Su, Qu Cui, Aiyun Jin, Li Yang, Shan Fu, Jianfeng Zhou, Lugui Qiu, Xi Zhang, Aibin Liang, Hongmei Jing, Yuhua Li, Didier Blaise, Mohamad Mohty, Arnon Nagler^*, He Huang^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.

Original language	English
Pages (from-to)	111-118
Number of pages	8
Journal	Current Research in Translational Medicine
Volume	68
Issue number	3
DOIs	https://doi.org/10.1016/j.retram.2020.06.003
State	Published - Aug 2020
Externally published	Yes

Funding

Funders	Funder number
National Natural Science Foundation of China	81770201, 81730008
Science and Technology Department of Zhejiang Province
Science and Technology Program of Zhejiang Province	2018C03016-2

Keywords

COVID-19
Chimeric antigen receptor T-cells
Cytokine release syndrome
Immunocompromised
Relapsed/refractory hematological malignancies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.retram.2020.06.003

Cite this

Hu, Y., Tan Su Yin, E., Yang, Y., Wu, H., Wei, G., Su, J., Cui, Q., Jin, A., Yang, L., Fu, S., Zhou, J., Qiu, L., Zhang, X., Liang, A., Jing, H., Li, Y., Blaise, D., Mohty, M., Nagler, A., & Huang, H. (2020). CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. Current Research in Translational Medicine, 68(3), 111-118. https://doi.org/10.1016/j.retram.2020.06.003

@article{b3b62893c6784823985ac7d6c6371563,

title = "CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges",

abstract = "The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.",

keywords = "COVID-19, Chimeric antigen receptor T-cells, Cytokine release syndrome, Immunocompromised, Relapsed/refractory hematological malignancies",

author = "Yongxian Hu and {Tan Su Yin}, Elaine and Yingying Yang and Hengwei Wu and Guoqing Wei and Junwei Su and Qu Cui and Aiyun Jin and Li Yang and Shan Fu and Jianfeng Zhou and Lugui Qiu and Xi Zhang and Aibin Liang and Hongmei Jing and Yuhua Li and Didier Blaise and Mohamad Mohty and Arnon Nagler and He Huang",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Masson SAS",

year = "2020",

month = aug,

doi = "10.1016/j.retram.2020.06.003",

language = "אנגלית",

volume = "68",

pages = "111--118",

journal = "Current Research in Translational Medicine",

issn = "2452-3186",

publisher = "Elsevier Masson s.r.l.",

number = "3",

}

Hu, Y, Tan Su Yin, E, Yang, Y, Wu, H, Wei, G, Su, J, Cui, Q, Jin, A, Yang, L, Fu, S, Zhou, J, Qiu, L, Zhang, X, Liang, A, Jing, H, Li, Y, Blaise, D, Mohty, M, Nagler, A & Huang, H 2020, 'CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges', Current Research in Translational Medicine, vol. 68, no. 3, pp. 111-118. https://doi.org/10.1016/j.retram.2020.06.003

TY - JOUR

T1 - CAR T-cell treatment during the COVID-19 pandemic

T2 - Management strategies and challenges

AU - Hu, Yongxian

AU - Tan Su Yin, Elaine

AU - Yang, Yingying

AU - Wu, Hengwei

AU - Wei, Guoqing

AU - Su, Junwei

AU - Cui, Qu

AU - Jin, Aiyun

AU - Yang, Li

AU - Fu, Shan

AU - Zhou, Jianfeng

AU - Qiu, Lugui

AU - Zhang, Xi

AU - Liang, Aibin

AU - Jing, Hongmei

AU - Li, Yuhua

AU - Blaise, Didier

AU - Mohty, Mohamad

AU - Nagler, Arnon

AU - Huang, He

PY - 2020/8

Y1 - 2020/8

N2 - The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.

AB - The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.

KW - COVID-19

KW - Chimeric antigen receptor T-cells

KW - Cytokine release syndrome

KW - Immunocompromised

KW - Relapsed/refractory hematological malignancies

UR - http://www.scopus.com/inward/record.url?scp=85087317374&partnerID=8YFLogxK

U2 - 10.1016/j.retram.2020.06.003

DO - 10.1016/j.retram.2020.06.003

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 32620465

AN - SCOPUS:85087317374

SN - 2452-3186

VL - 68

SP - 111

EP - 118

JO - Current Research in Translational Medicine

JF - Current Research in Translational Medicine

IS - 3

ER -

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this